PBA
BLTE

Paradigm Biocapital Advisors’s Belite Bio BLTE Stock Holding History

Paradigm Biocapital Advisors’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$178M Buy
+1,114,784
New +$187M 3.63% 9

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Paradigm Biocapital Advisors's BLTE Position: Q1 2026 in Review

Paradigm Biocapital Advisors opened a new position in Belite Bio (BLTE) in Q1 2026: 1,114,784 shares worth $178M. The stake represents 3.63% of the portfolio and ranks #9 among its holdings.

75 funds tracked by Wall St. Rank hold BLTE as of Q1 2026.

  • Paradigm Biocapital Advisors held 1,114,784 shares of Belite Bio worth $178M as of Q1 2026.
  • Belite Bio was a new Paradigm Biocapital Advisors position in Q1 2026.
  • Belite Bio made up 3.63% of Paradigm Biocapital Advisors's portfolio in Q1 2026, its #9 holding.
  • 75 funds tracked by Wall St. Rank held Belite Bio as of Q1 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2026, filed 15 May 2026.